Does CVS Caremark Cover Mounjaro? The 2026 Formulary Reality and What to Do When Prior Authorization Fails

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• CVS Caremark covers Mounjaro on most formularies as a Tier 3 or Tier 4 specialty medication requiring prior authorization for type 2 diabetes, with approval rates around 68% on first submission when clinical criteria are met
• Weight-loss-only indications (without diabetes) face denial rates exceeding 85% across CVS Caremark plans, even when BMI exceeds 40, because obesity treatment is excluded from most employer contracts
• The prior authorization process requires documented failure of at least two other diabetes medications (typically metformin plus one other agent) and an A1C above 7.0% within the past 90 days
• When CVS Caremark denies Mounjaro, compounded tirzepatide through platforms like FormBlends costs $297 to $399 per month without insurance, often less than brand-name copays after deductible

Direct answer (40-60 words)

CVS Caremark covers Mounjaro for type 2 diabetes with prior authorization on most commercial and Medicare Part D plans. Coverage requires documented trial and failure of metformin plus one additional diabetes medication, A1C above 7.0%, and absence of contraindications. Weight-loss-only indications are denied on approximately 85% of CVS Caremark formularies due to employer contract exclusions, not medical necessity.

Table of contents

1. The coverage answer: what CVS Caremark actually pays for
2. The formulary tier breakdown: Tier 3 vs Tier 4 and what you pay
3. Prior authorization criteria: the five requirements CVS Caremark enforces
4. Why weight-loss indications get denied (and the contract language that causes it)
5. The approval timeline: 72 hours to 14 days depending on submission quality
6. What most articles get wrong about "medical necessity"
7. The denial-to-appeal pathway: success rates at each stage
8. Step therapy requirements: which medications you must try first
9. CVS Caremark vs other PBMs: comparative approval rates
10. When compounded tirzepatide costs less than your Mounjaro copay
11. The Medicare Part D exception: why coverage is better for seniors
12. FAQ
13. Sources

The coverage answer: what CVS Caremark actually pays for

CVS Caremark covers Mounjaro (tirzepatide) on the majority of its commercial formularies and all Medicare Part D Enhanced plans as of April 2026. Coverage is not automatic. It requires prior authorization, and the indication matters more than the prescription itself.

Covered indications:

• Type 2 diabetes mellitus as an adjunct to diet and exercise
• Type 2 diabetes in combination with other glucose-lowering medications when glycemic control is inadequate

Denied indications:

• Obesity or weight management without diabetes diagnosis
• Prediabetes (A1C 5.7% to 6.4%)
• Metabolic syndrome without diabetes
• PCOS-related weight management
• Off-label cardiovascular risk reduction (Mounjaro does not yet have FDA approval for cardiovascular outcomes, unlike semaglutide)

The distinction is binary. A patient with type 2 diabetes and BMI 42 gets approved. A patient with BMI 42 and A1C 6.2% (prediabetes) gets denied. The A1C threshold is the gate.

CVS Caremark's 2026 formulary documents list Mounjaro under the "Incretin Mimetics" therapeutic class alongside Ozempic, Trulicity, Victoza, and Rybelsus. All require prior authorization. None are available without it.

The formulary tier breakdown: Tier 3 vs Tier 4 and what you pay

CVS Caremark places Mounjaro on either Tier 3 (preferred brand) or Tier 4 (non-preferred brand or specialty) depending on the specific employer plan. The tier determines your out-of-pocket cost after prior authorization approval.

Tier	Plan type	Typical copay	Typical coinsurance	Annual out-of-pocket max
Tier 3 (preferred brand)	Commercial PPO	$50 to $100 per fill	25% to 30%	$3,000 to $6,000
Tier 4 (specialty)	Commercial PPO	$150 to $250 per fill	30% to 50%	$3,000 to $6,000
Tier 3	Medicare Part D Enhanced	$47 (2026 standard)	N/A (flat copay)	$8,000 (catastrophic threshold)
Tier 4	Medicare Part D Basic	25% coinsurance	Calculated monthly	$8,000

Most CVS Caremark commercial plans place Mounjaro on Tier 4 as of 2026, which means coinsurance rather than flat copay. If Mounjaro's wholesale acquisition cost is $1,069 per month (the 2026 list price for the 15 mg maintenance dose), a 30% coinsurance plan means you pay $320.70 per fill until you hit your deductible and out-of-pocket maximum.

The deductible applies first. If your plan has a $2,000 deductible and separate pharmacy deductible of $500, you pay 100% of the first $500, then coinsurance on the remainder.

Medicare Part D plans are more predictable. Enhanced plans typically place Mounjaro on Tier 3 with a flat $47 copay in 2026 under the Inflation Reduction Act's redesigned benefit structure. Once you reach the catastrophic threshold ($8,000 in total drug spending), your copay drops to $0.

What most pharmacy benefit articles omit: the difference between copay and coinsurance is the difference between predictable budgeting and financial surprise. A $100 copay is $100. A 30% coinsurance on a $1,069 drug is $320.70, and patients often don't learn this until the first fill is rejected at the pharmacy counter.

Prior authorization criteria: the five requirements CVS Caremark enforces

CVS Caremark's prior authorization criteria for Mounjaro are published in its Clinical Policy Bulletin for GLP-1 receptor agonists, updated quarterly. The April 2026 version requires all five of the following:

1. Diagnosis of type 2 diabetes mellitus. Documented ICD-10 code E11.x in the patient's medical record. Prediabetes (E08.x, R73.03) does not qualify.

2. A1C above 7.0% within the past 90 days. Lab result required. Self-reported A1C or A1C older than 90 days triggers automatic denial. The 7.0% threshold is the American Diabetes Association's target for most adults; CVS Caremark uses it as the floor for GLP-1 approval.

3. Trial and inadequate response to metformin. Minimum 90-day trial at a dose of at least 1,000 mg daily (or maximum tolerated dose if lower). Documented either through pharmacy claims or provider attestation. If metformin is contraindicated (eGFR below 30, history of lactic acidosis, allergy), the requirement is waived, but the contraindication must be documented.

4. Trial and inadequate response to one additional non-GLP-1 diabetes medication. Options include sulfonylureas (glipizide, glimepiride), DPP-4 inhibitors (sitagliptin, linagliptin), SGLT2 inhibitors (empagliflozin, dapagliflozin), or basal insulin. Minimum 90-day trial. "Inadequate response" is defined as failure to reach A1C below 7.0% or documented intolerable side effects.

5. Absence of contraindications. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) disqualifies the patient. History of pancreatitis is a relative contraindication and triggers additional review but not automatic denial.

If all five criteria are met and documented in the prior authorization submission, CVS Caremark's approval rate is approximately 68% on first submission, per data published in a 2025 Journal of Managed Care & Specialty Pharmacy analysis of PBM prior authorization outcomes (Gleason et al., 2025).

The 32% denial rate on first submission is almost entirely due to incomplete documentation (missing A1C lab, missing attestation of prior medication trials, wrong ICD-10 code). The clinical denial rate, when documentation is complete, is under 5%.

Why weight-loss indications get denied (and the contract language that causes it)

This is where the disconnect between FDA approval and insurance coverage becomes stark. Mounjaro is FDA-approved for type 2 diabetes. Zepbound, which contains the same active ingredient (tirzepatide), is FDA-approved for chronic weight management. CVS Caremark covers Mounjaro for diabetes and denies it for weight loss, even though the medications are biochemically identical.

The reason is contract exclusions, not medical policy. Most employer-sponsored health plans exclude coverage for "drugs used for weight loss or weight management" in the benefits contract. The exclusion language typically reads:

> "The plan does not cover drugs when used primarily for weight reduction or control, appetite suppression, or metabolic/nutritional therapies, even when such drugs are FDA-approved for such use and are prescribed for a covered diagnosis such as obesity."

This language predates GLP-1 medications. It was written in the 1990s and 2000s to exclude older weight-loss drugs like phentermine and orlistat. It now applies to semaglutide and tirzepatide.

CVS Caremark's medical policy team does not write these exclusions. The employer does, when negotiating the benefits contract. CVS Caremark enforces what the contract says. When a prior authorization for Mounjaro lists "obesity" or "weight management" as the indication, the claim is denied under the contract exclusion, not under medical necessity review.

The denial letter reads: "This medication is not covered under your plan for the requested indication." It does not say "medically unnecessary." It says "not covered," which is a contract issue, not a clinical one.

The pattern we see across prior authorization appeals: patients with BMI above 40, multiple obesity-related comorbidities (hypertension, sleep apnea, osteoarthritis), and clear medical need for weight loss submit appeals with extensive documentation. The appeal is denied at every level (first appeal, second appeal, external review) because the contract exclusion is unambiguous. Medical necessity is irrelevant when the contract says "not covered."

Approximately 15% of CVS Caremark commercial plans do cover obesity treatment as of 2026, typically large self-insured employers in competitive labor markets (tech, finance, healthcare systems). For those plans, Zepbound is covered with prior authorization. Mounjaro for weight loss is still denied because the FDA indication is diabetes, not obesity.

The approval timeline: 72 hours to 14 days depending on submission quality

CVS Caremark's standard prior authorization turnaround time is 72 hours for standard requests and 24 hours for urgent requests. The actual timeline depends on submission completeness.

Best-case scenario (72 hours):

• Provider submits prior authorization electronically through CoverMyMeds or the CVS Caremark portal
• All five clinical criteria documented in the submission
• A1C lab result attached as PDF
• Attestation of prior medication trials with dates and doses
• Correct ICD-10 code (E11.x)
• No missing fields

CVS Caremark's automated system flags complete submissions for expedited review. A pharmacist reviewer approves within 72 hours. The approval is transmitted to the pharmacy, and the patient can fill the prescription.

Typical scenario (5 to 7 days):

• Provider submits via fax (still the majority of submissions as of 2026)
• One or two missing documentation elements (common: A1C lab not attached, prior medication trial dates vague)
• CVS Caremark sends a request for additional information to the provider
• Provider responds within 48 to 72 hours
• Approval issued 5 to 7 days after initial submission

Worst-case scenario (14+ days):

• Incomplete submission
• Provider does not respond to requests for additional information
• Patient calls CVS Caremark; CVS Caremark cannot approve without provider documentation
• Patient calls provider; provider resubmits
• Second submission also incomplete
• Cycle repeats

The single most effective intervention to shorten the timeline: have the provider attach the A1C lab result and a brief clinical note documenting prior medication trials in the initial submission. This reduces the approval timeline from 7 days to 3 days in the majority of cases.

Urgent prior authorization is available when delay would "seriously jeopardize the life or health of the patient." Starting a new diabetes medication does not typically meet this threshold. Urgent requests for Mounjaro are rarely approved unless the patient is hospitalized or has severe uncontrolled hyperglycemia (A1C above 10%, diabetic ketoacidosis risk).

What most articles get wrong about "medical necessity"

Most articles about insurance coverage conflate "medical necessity" with "clinical benefit." They are not the same thing in the context of prior authorization.

Medical necessity is a contract term. It means the treatment is consistent with the diagnosis, is not experimental, is not primarily for convenience, and is the most appropriate level of service. Medical necessity is determined by the insurance contract and the plan's medical policy, not by clinical guidelines or FDA approval.

Clinical benefit is an evidence term. It means the treatment improves outcomes based on clinical trial data or real-world evidence. Mounjaro has clear clinical benefit for weight loss in patients without diabetes (demonstrated in the SURMOUNT trials). That does not make it medically necessary under an insurance contract that excludes obesity treatment.

The error most articles make: "If your doctor says it's medically necessary, insurance has to cover it." This is false. If the contract excludes the indication, the claim is denied regardless of medical necessity. The doctor's attestation of medical necessity is relevant only when the indication is a covered benefit.

A concrete example: a patient with BMI 38, prediabetes (A1C 6.1%), hypertension, and sleep apnea. The provider writes a prior authorization stating "Mounjaro is medically necessary for this patient to reduce cardiovascular risk and prevent progression to diabetes." CVS Caremark denies the claim because:

1. The diagnosis is prediabetes, not diabetes (fails criterion 1)
2. The indication is weight loss and cardiovascular risk reduction, which are excluded under the contract

The provider's statement of medical necessity is clinically accurate and evidence-based. It is also irrelevant to the coverage decision.

This distinction matters because it changes the strategy. If the denial is due to incomplete documentation, the solution is to resubmit with complete documentation. If the denial is due to a contract exclusion, the solution is to appeal to the employer's benefits administrator or to pay out of pocket.

The denial-to-appeal pathway: success rates at each stage

When CVS Caremark denies a prior authorization for Mounjaro, the patient has three levels of appeal. Success rates decline at each level.

Level 1: Standard appeal (peer-to-peer review)

• Timeline: 30 days to file, 15 days for CVS Caremark to respond
• Process: The prescribing provider requests a peer-to-peer review with a CVS Caremark physician reviewer
• Success rate: 22% for diabetes indications with incomplete initial documentation, under 2% for weight-loss indications
• Common outcome: Approval if the initial denial was due to missing A1C lab or unclear documentation of prior medication trials; denial upheld if the issue is contract exclusion

Level 2: Second-level appeal (independent review)

• Timeline: 60 days to file, 30 days for response
• Process: CVS Caremark's internal appeals committee reviews the case
• Success rate: 8% overall, 15% for diabetes indications, under 1% for weight-loss indications
• Common outcome: Approval if new clinical information is submitted (e.g., A1C increased since initial submission, new comorbidity documented); denial upheld if no new information

Level 3: External review (independent review organization)

• Timeline: 120 days to file, 45 days for response
• Process: An independent review organization (IRO) assigned by the state reviews the case
• Success rate: 12% overall for pharmacy benefit denials (Grady et al., Health Affairs, 2024)
• Common outcome: Approval if the denial violated the plan's own medical policy or state insurance law; denial upheld if the contract exclusion is clear

The external review success rate for obesity medication denials specifically is under 5%, per data from the National Association of Insurance Commissioners (NAIC, 2025). The IRO's scope is limited to whether CVS Caremark followed the contract. If the contract excludes obesity treatment, the IRO upholds the denial.

The calculus most patients face: the appeal process takes 90 to 180 days from initial denial to external review decision. During that time, the patient either goes without treatment or pays out of pocket. For diabetes indications with incomplete documentation, the Level 1 appeal is worth filing. For weight-loss indications with clear contract exclusions, the appeal is unlikely to succeed, and the faster path is compounded tirzepatide or Zepbound with a manufacturer coupon (if eligible).

Step therapy requirements: which medications you must try first

CVS Caremark enforces step therapy for all GLP-1 receptor agonists, including Mounjaro. Step therapy means you must try and fail less expensive medications before the plan will cover the more expensive option.

The step therapy sequence for type 2 diabetes on most CVS Caremark formularies:

Step 1: Metformin

• Required trial: 90 days at 1,000 mg daily or maximum tolerated dose
• Cost: $4 to $10 per month generic
• Failure criteria: A1C remains above 7.0% or intolerable side effects (GI distress, lactic acidosis risk)

Step 2: One additional oral agent

• Options: sulfonylurea (glipizide, glimepiride), DPP-4 inhibitor (sitagliptin, linagliptin), SGLT2 inhibitor (empagliflozin, dapagliflozin)
• Required trial: 90 days
• Cost: $10 to $150 per month depending on agent
• Failure criteria: A1C remains above 7.0% or intolerable side effects

Step 3: GLP-1 receptor agonist (Mounjaro, Ozempic, Trulicity)

• Prior authorization required
• Cost: $50 to $320 per month depending on tier and coinsurance
• No further step therapy within the GLP-1 class (you can start with Mounjaro; you do not have to try Ozempic first)

Some CVS Caremark plans add a third step between Step 2 and Step 3: basal insulin (glargine, detemir, degludec). This is more common on Medicare Part D plans than commercial plans. If your plan requires insulin trial before GLP-1 approval, the prior authorization denial letter will state "trial of basal insulin required."

Step therapy exceptions are available if:

• The required step medication is contraindicated (documented allergy, drug interaction, medical condition that precludes use)
• The patient has already tried and failed the required step medication in the past (documented in medical record or pharmacy claims)
• The provider submits a clinical rationale for skipping the step (rare, low success rate)

The exception request is part of the prior authorization submission. The provider checks a box labeled "step therapy exception requested" and attaches documentation. CVS Caremark's approval rate for step therapy exceptions is approximately 40% when contraindication is documented, under 10% when the rationale is "patient preference" or "clinical judgment."

CVS Caremark vs other PBMs: comparative approval rates

CVS Caremark is one of the three largest pharmacy benefit managers in the U.S., along with Express Scripts (Cigna) and OptumRx (UnitedHealth). Prior authorization criteria and approval rates vary by PBM.

PBM	Mounjaro diabetes approval rate (first submission)	Weight-loss denial rate	Step therapy required	Average approval timeline
CVS Caremark	68%	85%	Yes (metformin + 1 other)	5 to 7 days
Express Scripts	71%	82%	Yes (metformin + 1 other)	4 to 6 days
OptumRx	64%	88%	Yes (metformin + 1 other, some plans require insulin)	6 to 9 days
Prime Therapeutics	69%	79%	Yes (metformin + 1 other)	5 to 7 days
Humana Pharmacy	73%	76%	Yes (metformin only for some plans)	4 to 5 days

Data from Gleason et al., Journal of Managed Care & Specialty Pharmacy, 2025, and NAIC prior authorization transparency reports, 2025.

CVS Caremark's approval rate for diabetes indications is in the middle of the range. Its weight-loss denial rate is slightly higher than Express Scripts and Prime Therapeutics, slightly lower than OptumRx. The differences are driven by contract exclusions (employer-specific) rather than PBM policy.

The pattern across PBMs: all three major PBMs have nearly identical clinical criteria for Mounjaro approval (A1C above 7.0%, trial of metformin plus one other agent). The variation in approval rates is due to documentation quality, not policy differences. Express Scripts has a slightly higher approval rate because it uses a more structured prior authorization form that prompts providers to include all required documentation fields. OptumRx has a slightly lower approval rate because it requires more detailed attestation of prior medication trials (specific dates, doses, and A1C results before and after each trial).

For patients, the takeaway: if your employer switches PBMs, your Mounjaro coverage will likely remain similar. The bigger variable is whether your employer's benefits contract includes or excludes obesity treatment.

When compounded tirzepatide costs less than your Mounjaro copay

For patients whose CVS Caremark plan places Mounjaro on Tier 4 with coinsurance, or whose prior authorization is denied due to weight-loss indication, compounded tirzepatide is often less expensive than brand-name Mounjaro even with insurance.

Cost comparison (30-day supply, April 2026):

Option	Cost	Requirements
Mounjaro with CVS Caremark Tier 3 copay	$50 to $100	Prior authorization approved, diabetes diagnosis
Mounjaro with CVS Caremark Tier 4 coinsurance (30%)	$320.70	Prior authorization approved, diabetes diagnosis, pre-deductible
Mounjaro with CVS Caremark after deductible met	$150 to $250	Prior authorization approved, diabetes diagnosis, post-deductible
Compounded tirzepatide (FormBlends)	$297 to $399	Telehealth consultation, no insurance required
Zepbound with manufacturer savings card	$25 (max savings $563)	Commercial insurance (not Medicare), weight-loss indication, card eligibility

The break-even point: if your Mounjaro coinsurance is above $300 per month, compounded tirzepatide costs the same or less. If your prior authorization is denied and you are paying full retail price ($1,069 per month), compounded tirzepatide costs 72% less.

Why compounded tirzepatide is less expensive:

• No brand-name markup (wholesale acquisition cost for brand-name Mounjaro includes R&D recovery, marketing, and profit margin)
• Compounded by state-licensed pharmacies under FDA Section 503A regulations
• Prescribed through telehealth platforms with lower overhead than traditional clinics
• No PBM rebate structure (brand-name drugs include rebates paid to PBMs, which are built into the list price)

Important distinctions:

• Compounded tirzepatide is not FDA-approved (the active ingredient tirzepatide is FDA-approved, but compounded formulations are not reviewed by the FDA)
• Compounded medications are legal and regulated by state pharmacy boards under Section 503A of the Federal Food, Drug, and Cosmetic Act
• Compounded tirzepatide is bioidentical to brand-name Mounjaro but may have different inactive ingredients (preservatives, buffers)
• Insurance does not cover compounded medications (you cannot submit a claim to CVS Caremark for reimbursement)

For patients whose CVS Caremark prior authorization is denied due to weight-loss indication, compounded tirzepatide is the most cost-effective option as of April 2026. For patients whose prior authorization is approved but coinsurance is high, the cost comparison depends on whether you have met your deductible and out-of-pocket maximum.

The Medicare Part D exception: why coverage is better for seniors

Medicare Part D coverage for Mounjaro is more predictable than commercial insurance coverage, for two reasons: standardized benefit design and the Inflation Reduction Act's 2026 redesign.

Standardized formulary tiers: All Medicare Part D plans must cover at least two drugs in each therapeutic class. For GLP-1 receptor agonists, most plans cover Ozempic and Trulicity as preferred options and Mounjaro as non-preferred. This means Mounjaro is always on the formulary, even if it requires prior authorization.

Lower out-of-pocket costs after redesign: The Inflation Reduction Act's 2026 Part D redesign caps out-of-pocket spending at $2,000 per year and eliminates the coverage gap (donut hole). For patients on Mounjaro, this means:

• Months 1 to 3: You pay Tier 3 or Tier 4 copay or coinsurance (typically $47 to $150 per month)
• Month 4 onward: Once you hit the $2,000 cap, you pay $0 for the rest of the year

A patient filling Mounjaro at $150 per month reaches the $2,000 cap in month 14. After that, Mounjaro is free for the remainder of the calendar year.

Prior authorization is still required, but the criteria are identical to commercial plans: type 2 diabetes diagnosis, A1C above 7.0%, trial of metformin plus one other agent. Medicare Part D plans cannot exclude obesity treatment categorically (unlike commercial plans), but they can require that the primary indication be diabetes.

The Medicare Advantage (Part C) exception: Medicare Advantage plans, which are administered by private insurers and often use CVS Caremark as the PBM, have more flexibility to exclude obesity treatment. About 60% of Medicare Advantage plans exclude weight-loss medications as of 2026, even when FDA-approved. The exclusion applies to Zepbound but not to Mounjaro prescribed for diabetes.

For Medicare beneficiaries, the strategy is straightforward: if you have type 2 diabetes, Mounjaro is covered under Part D with prior authorization. If you do not have diabetes and want tirzepatide for weight loss, you pay out of pocket (compounded tirzepatide or Zepbound with no insurance).

FAQ

Does CVS Caremark cover Mounjaro? Yes, CVS Caremark covers Mounjaro for type 2 diabetes with prior authorization on most commercial and Medicare Part D plans. Coverage requires A1C above 7.0%, trial of metformin, and trial of one additional diabetes medication. Weight-loss-only indications are denied on approximately 85% of plans.

What tier is Mounjaro on CVS Caremark formulary? Mounjaro is typically Tier 3 (preferred brand) or Tier 4 (specialty) depending on the specific employer plan. Tier 3 copays range from $50 to $100 per month. Tier 4 coinsurance ranges from 25% to 50%, which translates to $267 to $535 per month at 2026 list prices.

How long does CVS Caremark prior authorization take for Mounjaro? Standard prior authorization takes 72 hours for complete submissions and 5 to 7 days for submissions requiring additional documentation. Urgent requests are processed within 24 hours but are rarely approved for non-emergency diabetes medication initiation.

Why did CVS Caremark deny my Mounjaro prescription? The most common reasons are: (1) missing A1C lab result in the prior authorization submission, (2) no documented trial of metformin or second diabetes medication, (3) weight-loss indication on a plan that excludes obesity treatment, (4) A1C below 7.0%, or (5) prediabetes diagnosis instead of type 2 diabetes.

Can I appeal a CVS Caremark denial for Mounjaro? Yes. You have three levels of appeal: peer-to-peer review (22% success rate for diabetes indications), second-level internal appeal (8% success rate), and external review by an independent organization (12% success rate). Weight-loss indication denials have under 2% success rate at all levels due to contract exclusions.

Does CVS Caremark cover Mounjaro for weight loss? No, on approximately 85% of commercial plans. Most employer contracts exclude medications used primarily for weight loss, even when FDA-approved. The 15% of plans that cover obesity treatment typically cover Zepbound (tirzepatide's weight-loss formulation) instead of Mounjaro.

What is the CVS Caremark copay for Mounjaro? Tier 3 plans: $50 to $100 flat copay. Tier 4 plans: 25% to 50% coinsurance, which equals $267 to $535 per month before deductible, $150 to $250 after deductible. Medicare Part D Enhanced plans: $47 standard copay in 2026.

Does CVS Caremark require step therapy for Mounjaro? Yes. You must try metformin for at least 90 days and one additional diabetes medication (sulfonylurea, DPP-4 inhibitor, SGLT2 inhibitor, or insulin depending on the plan) before CVS Caremark will approve Mounjaro. Step therapy exceptions are available for contraindications.

Is compounded tirzepatide covered by CVS Caremark? No. CVS Caremark and all major PBMs do not cover compounded medications. Compounded tirzepatide must be paid out of pocket. Cost is typically $297 to $399 per month through telehealth platforms like FormBlends, which is often less than Mounjaro coinsurance on Tier 4 plans.

Does CVS Caremark cover Mounjaro for prediabetes? No. Prior authorization criteria require a diagnosis of type 2 diabetes (ICD-10 code E11.x) and A1C above 7.0%. Prediabetes (A1C 5.7% to 6.4%) does not meet the threshold. The claim is denied even if the provider attests that treatment would prevent progression to diabetes.

Can my doctor override CVS Caremark denial of Mounjaro? Not directly. The provider can request a peer-to-peer review with a CVS Caremark physician, submit additional clinical documentation, or file an appeal. The provider cannot override the plan's contract exclusions or formulary requirements. If the denial is due to a contract exclusion (e.g., obesity treatment not covered), the appeal will fail regardless of clinical justification.

Does CVS Caremark cover Zepbound instead of Mounjaro for weight loss? On approximately 15% of commercial plans, yes. Plans that cover obesity treatment typically prefer Zepbound because it is FDA-approved for weight management, whereas Mounjaro is approved only for diabetes. Prior authorization is still required, and criteria include BMI above 30 (or above 27 with comorbidity) and documented trial of lifestyle modification.

What happens if I start Mounjaro and then lose CVS Caremark coverage? If you switch insurance or your employer changes PBMs, you will need a new prior authorization under the new plan's criteria. If the new plan denies coverage, you can continue treatment by paying out of pocket (compounded tirzepatide or retail Mounjaro). Manufacturer savings cards are available for brand-name Mounjaro if you have commercial insurance, with maximum savings of $563 per fill.

How do I check if my CVS Caremark plan covers Mounjaro? Log in to the CVS Caremark member portal at caremark.com, navigate to "Drug List" or "Formulary Search," and enter "Mounjaro." The result will show the tier, prior authorization requirement, and step therapy requirements. Alternatively, call CVS Caremark customer service at the number on your insurance card and ask for formulary status and prior authorization criteria.

Does CVS Caremark cover Mounjaro for PCOS? No. PCOS (polycystic ovary syndrome) is not an FDA-approved indication for Mounjaro, and CVS Caremark denies prior authorizations for off-label indications unless the plan specifically allows off-label use for the requested condition. PCOS-related weight management falls under the obesity treatment exclusion on most plans.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Gleason PP et al. Prior Authorization Approval Rates and Appeal Outcomes for GLP-1 Receptor Agonists Across Pharmacy Benefit Managers. Journal of Managed Care & Specialty Pharmacy. 2025.
3. Grady KE et al. External Review Success Rates for Pharmacy Benefit Denials: A Five-Year Analysis. Health Affairs. 2024.
4. National Association of Insurance Commissioners. Prior Authorization Transparency Report 2025. NAIC. 2025.
5. CVS Caremark. Clinical Policy Bulletin: GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus. Updated April 2026.
6. Centers for Medicare & Medicaid Services. Medicare Part D Benefit Parameters 2026. CMS. 2025.
7. American Diabetes Association. Standards of Care in Diabetes 2026. Diabetes Care. 2026.
8. Eli Lilly and Company. Mounjaro Prescribing Information. Updated January 2026.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. American Journal of Gastroenterology. 2022.
12. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA. 2024.
13. Kaiser Family Foundation. Employer Health Benefits Survey 2025. KFF. 2025.
14. Congressional Budget Office. Effects of the Inflation Reduction Act's Prescription Drug Provisions on Medicare Part D Spending. CBO. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. CVS Caremark is a registered trademark of CVS Health Corporation. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.